Newsletter June 2024
How does Newcells works with their clients?
Listen to our CEO, Dr Mike Nicholds explaining.
Webinar on demand: Moving compounds to IND using predictive retinal models.
Our panel of experts discusses regulatory, technology and scientific perspectives to accelerate your retinal therapeutic compound through the clinical development.
Watch the webinar here.
Paper Alert: Read our latest scientific publication on nephrotoxicity
In this study, we assessed the nephrotoxicity of two formulations of polymyxin B using a validated model of primary human proximal tubule cells. The ability to measure responses such as kidney injury biomarkers in vitro correlates with in vivo measurement, demonstrating that aProximateTM is a powerful tool to rapidly evaluate the nephrotoxicity and renal uptake of novel antibiotic formulations.
Reference
Pye, K.; Tasinato, E.; Shuttleworth, S.; Devlin, C.; Brown, C. Comparison of the Impact of VRP-034 and Polymyxin B upon Markers of Kidney Injury in Human Proximal Tubule Monolayers In Vitro. Antibiotics 2024, 13, 530.
Read the paper here
Technology Spotlight: Kidney fibrosis
Latest development of primary model for focal segmental Glomerulosclerosis
Glomerular fibrotic disease modelling now made possible with the ability to model the glomerular filtration barrier (GFB) detecting injury, phenotypic changes and cellular damage in vitro.
View the poster presented at CKD Summit 2024
Company News: Newcells strengthens executive team and expands US team
As the company continues to focus on driving expansion and technological innovation in response to increased market demand for drug discovery workflow, key leadership changes have taken place within Newcells’ executive team: Dr Valeria Chichagova has taken the role of Director of Technology; Dr Colin Brown is now Chief Scientific Officer and Professor Lyle Armstrong, the Company’s Co-Founder has become a Scientific Advisor. In addition, commercial appointments within its US team have been made to further support its global customer network.
Conferences: Meet us to talk about science
JSOT 51st
Annual Meeting
3rd July 2024 – 5 July 2024
Fukuoka, Japan
Visit us at booth #21 to discuss our in vitro solutions for safety assessment with Dr Colin Brown, and Rhys Powell
8th Annual IPF Summit
20th August 2024 – 22 August 2024
Boston, MA, USA
We look forward to welcoming you to discuss our unique lung models and their applications for fibrosis studies with our head of lung – Dr Megan Webster
5th GTX Summit
10th September – 12 September 2024
Boston, MA , USA
We look forward to welcoming you to discuss our unique retina models and their applications for ophthalmic gene therapy studies with Anthony Kayas
Visit our website to find out more about our in vitro models
Kidney Nephron Models
Screen your drugs using multi-species models of the glomerulus and proximal tubule to gain predictive insights on safety, pharmacokinetics, and efficacy
Retina Models
A human iPSC derived suite of organoid and 3-D models capable of modelling retinopathies for efficacy and safety studies
Lung Airway Models
Use our platform of lung models and assays to understand efficacy in pulmonary fibrotic diseases in high-throughput and high-content formats.
Share on social media:
Don't miss out on our latest innovations: follow us on Linkedin
